City of Hope to Use Sequenom's MassARRAY® System and Portfolio of Application Tools

Sequenom, Inc. has announced that City of Hope National Medical Center (City of Hope) has purchased Sequenom's MassARRAY genetic analysis system and portfolio of application tools for the Center's molecular marker research and individualized cancer care initiatives.

"We will utilize Sequenom's platform and applications for quantitative gene expression and methylation (epigenetic) studies," said Garry Larson, Ph.D., Associate Research Scientist, City of Hope.  

"In addition, we will use the high throughput genotyping application as an integral part of our on-going research both to identify individuals at high risk for developing cancer, and to aid in the development of therapeutic modalities based on the unique genetic profile of a given patient."

"The MassARRAY platform is unique and particularly well-suited to our needs because it enables us to perform many different types of analysis in a cost-effective manner and on a single platform."

"The National Cancer Institute has designated City of Hope a 'Comprehensive Cancer Center,' one of just a handful of such elite institutions nationwide, and we are excited that their researchers will use the MassARRAY platform for their pioneering cancer studies involving epigenetics," said Harry Stylli, Ph.D., President and Chief Executive Officer of Sequenom. 

"Epigenetic analysis has significant clinical potential in cancer research and other fields. Our MassARRAY technology enables this important analysis and will help accelerate advancements in understanding and potentially treating cancer and other diseases."